DOI: 10.1055/s-00000069

Seminars in Liver Disease

References


A randomized, double-blind, multicenter phase III study of brivanib versus placebo as adjuvant therapy to trans-arterial chemo-embolization (TACE) in patients with unresectable hepatocellular carcinoma (The BRISK TA Study).
Available at:
http://clinicaltrials.gov/ct2/show/NCT00908752 . Accessed January 11, 2012

Download Bibliographical Data

Search in: